A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin

Annals of Neurology

Volumn 42, Issue 6, 1997, Pages 857-865

  Algra, ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; PHENPROCOUMON; WARFARIN;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ASPIRIN; BRAIN ISCHEMIA; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 0031455701     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420606     Document Type: Article

References (32)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
2. Algra A, van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia. J Neurol Neurosurg Psychiatry 1996;60:197-199
3. Warlow C. Secondary prevention of stroke. Lancet 1992;339: 724-727
4. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266
5. The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-994
6. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152
7. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343: 499-503
8. The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-708
9. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324: 1865-1875
10. Jonas S. Anticoagulant therapy in cerebrovascular disease: review and meta-analysis. Stroke 1988;19:1043-1048
11. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262
12. Loeliger EA, Poller L, Samana M, et al. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 1985;54:515-517
13. Palareti G, Leali N, Coccheri S, et al, on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428
14. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607
15. Bamford JL, Sandercock PAG, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989;20:828 (Letter)
16. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239
17. Task force of the working group on arrhythmias of the European Society of Cardiology. The early termination of clinical trials: causes, consequences, and control - with special reference to trials in the field of arrhythmias and sudden death. Circulation 1994;89:2892-2907
18. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-202
19. Egret statistical package. Seattle: Statistics and Epidemiology Research Corporation, 1990
20. Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996;27:1349-1355
21. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17
22. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5-10
23. Greenberg SM, Vonsattel JP, Stakes JW, et al. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993;43:2073-2079
24. Sloan MA, Price TR, Petito CK, et al, for the TIMI Investigators. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: The Thrombolysis in Myocardial Infarction (TIMI) II pilot and randomized clinical trial combined experience. Neurology 1995;45:649-658
25. Wijdicks EFM, Jack CR Jr. Intracerebral hemorrhage after fibrinolytic therapy for acute myocardial infarction. Stroke 1993; 24:554-557
26. Kappelle LJ, van Latum JC, Koudstaal PJ, van Gijn J, for the Dutch TIA Study Group. Transient ischaemic attacks and small-vessel disease. Lancet 1991;337:339-341
27. Algra A, van Gijn J. Science unblinded. Lancet 1994;343:1040 (Letter)
28. Mohr JP, the WARSS Group. Design considerations for the Warfarin-Antiplatelet Recurrent Stroke Study. Cerebrovasc Dis 1995;5:156-157
29. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546
30. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638
31. Fihn SD, Callahan CM, Martin DC, et al, for the National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-979
32. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76: 12-16